New antibody combo tackles Hard-to-Treat cancers in early trial
NCT ID NCT04635995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030-3722, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
- Money worries and cancer: can talking about both ease the burden?
- Digital navigator aims to cut financial toxicity for young adults with cancer
- Can a simple checklist boost recovery after cancer surgery?
- Leftover blood samples could unlock new medical discoveries